Atlas Trials

Sinotau Pharmaceutical Group

17 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Sinotau Pharmaceutical Group

RecordFirmDate
PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy (NCT07443696)Sinotau Pharmaceutical Group2025-12-18
Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR) (NCT07439133)Sinotau Pharmaceutical Group2025-11-14
A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese Adults (NCT07149831)Sinotau Pharmaceutical Group2025-06-07
Diagnostic Efficacy and Safety of Flotufolastat F-18 Injection in Subjects With Biochemical Recurrence of Prostate Cancer (NCT07115277)Sinotau Pharmaceutical Group2025-03-14
Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary Stenosis (NCT07187895)Sinotau Pharmaceutical Group2024-12-19
Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD (NCT07115238)Sinotau Pharmaceutical Group2024-11-20
A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms (NCT06398444)Sinotau Pharmaceutical Group2024-06-11
Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer (NCT06081686)Sinotau Pharmaceutical Group2023-09-13
A Study to Evaluate XTR006 in Chinese Volunteers (NCT06151795)Sinotau Pharmaceutical Group2023-06-12
Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects (NCT06151808)Sinotau Pharmaceutical Group2022-09-01
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs (NCT05459844)Sinotau Pharmaceutical Group2022-08-31
Evaluation of XTR004 as a Novel 18F-labeled PET MPI Tracer in Diagnosis of Known or Suspected CAD (NCT05885841)Sinotau Pharmaceutical Group2022-02-15
XTR003 PET Radiotracer for the Detection of Viable Myocardium (NCT05885854)Sinotau Pharmaceutical Group2021-12-15
Clinical Study on PET Imaging, Distribution and PK of 89Zr-CD147 in Patients With Solid Tumors (NCT04841421)Sinotau Pharmaceutical Group2021-05-01
A Phase I Study to Evaluate XTR003 in Healthy Chinese Volunteers (NCT05136391)Sinotau Pharmaceutical Group2021-03-29
A Study of XTR004 Radiotracer in Healthy Volunteers (NCT05195879)Sinotau Pharmaceutical Group2021-03-23
A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population (NCT05527288)Sinotau Pharmaceutical Group2021-01-28

Track Sinotau Pharmaceutical Group automatically

Every clearance here is in the API, with alerts when new ones post.